Nautisol (Prochlorperazine Maleate)

Prochlorperazine blocks dopamine D2 receptors in the brain’s chemoreceptor trigger zone, reducing the signal that initiates vomiting. Its additional antagonism of histamine, muscarinic, and alpha‑adrenergic receptors contributes to its anti‑vertigo, anti‑nausea, and antipsychotic actions.

The appropriate dose of Nautisol is determined by the prescribing clinician based on the patient’s condition, age, weight, and response to therapy. Dosage regimens vary for antiemetic versus antipsychotic indications and should follow the prescriber’s instructions.

Safety data for prochlorperazine in pregnancy and lactation are limited. The prescriber should weigh potential benefits against possible risks and consider alternative therapies when possible. Women who are pregnant, planning to become pregnant, or breastfeeding should discuss use with their healthcare provider.

To request Nautisol, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, confirming trade or institutional credentials before providing pricing, availability, shipping details, and any necessary import documentation.

Compared with other antiemetics such as ondansetron or metoclopramide, prochlorperazine offers a broader receptor profile, affecting dopamine, histamine, and muscarinic pathways. This can provide effective control of both nausea and vertigo, but it may also carry a higher risk of extrapyramidal side effects.

Nautisol should be stored at room temperature, below 25 °C, in its original packaging. Keep the product away from moisture, direct sunlight, and excessive heat to maintain its stability and potency throughout its shelf life.

Nautisol is taken orally, usually as a tablet or other oral formulation, with or without food as directed by the prescriber. The exact method of administration, including timing relative to meals, should follow the healthcare professional’s guidance.

Serious risks include extrapyramidal symptoms such as dystonia or tardive dyskinesia, neuroleptic malignant syndrome, severe hypotension, and cardiac arrhythmias like QT prolongation. Patients should be monitored closely for these events, and any concerning symptoms should prompt immediate medical evaluation.

Nautisol is contraindicated in individuals with known hypersensitivity to prochlorperazine or other phenothiazines, those taking monoamine oxidase inhibitors, and patients with severe cardiovascular disorders that could be worsened by hypotension. The prescriber should assess each patient’s medical history before initiating therapy.